Hepatitis

Glecaprevir/Pibrentasvir Is Safe, Efficacious for HCV/HIV-1 Coinfection

Glecaprevir/Pibrentasvir Is Safe, Efficacious for HCV/HIV-1 Coinfection

Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.

First Human Case of Rat Strain of Hepatitis E Found

First Human Case of Rat Strain of Hepatitis E Found

The first human case of a strain of hepatitis E previously found only in rats was diagnosed in a Hong Kong man who received a liver transplant in May 2017.

Availability of Generic Antivirals for Hepatitis B Increasing

Availability of Generic Antivirals for Hepatitis B Increasing

Drop in median price of WHO-prequalified generic tenofovir from 208 to 32 from 2004 to 2016

Poor Adherence Contributes to Inadequate Uptake of Multidose Hepatitis Vaccine Schedules

Poor Adherence Contributes to Inadequate Uptake of Multidose Hepatitis Vaccine Schedules

By

Adherence and completion to multidose vaccine schedules for hepatitis A, B, and A-B are low, thereby rendering vaccination ineffective.

Project ECHO: Educational Support to Improve Hepatitis Care

Project ECHO: Educational Support to Improve Hepatitis Care

By

Project ECHO at Los Angeles Christian Health Center contributes to improved care of HCV in underserved populations.

Demographic Insights Into Hepatitis Vaccination Practices

Demographic Insights Into Hepatitis Vaccination Practices

By

From 2007 to 2015, the majority of initial hepatitis A, B, and A/B vaccinations were administered by primary care providers.

CDC Issues Updated Advisory Regarding Outbreaks of Hepatitis A

CDC Issues Updated Advisory Regarding Outbreaks of Hepatitis A

By

Of the 2500 cases of hepatitis A infection reported between January 2017 and April 2018, 68% were among persons who reported drug use (injection and non-injection), homelessness, or both.

Healthcare Program Obtains 93% of Prior Authorization Approvals for HCV Medications

Healthcare Program Obtains 93% of Prior Authorization Approvals for HCV Medications

By

The Respectful & Equitable Access to Comprehensive Healthcare program obtained 93% of prior authorization approvals for hepatitis C medications.

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

By

A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.

More Comprehensive HDV Surveillance Needed in High-Risk Individuals

More Comprehensive HDV Surveillance Needed in High-Risk Individuals

Future studies might focus on the use of electronic medical record warning systems or other prompts to improve diagnostic test use in at-risk individuals.

Direct-Acting Antivirals Improve Liver Transplant Survival

Direct-Acting Antivirals Improve Liver Transplant Survival

Direct-acting antivirals improved the survival of patients undergoing liver transplantation for HCV-related liver disease.

HCV treatment with direct antiviral agents improves carotid atherosclerosis

HCV treatment with direct antiviral agents improves carotid atherosclerosis

By

Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.

Hepatitis B infection prevention: ACIP updated recommendations

Hepatitis B infection prevention: ACIP updated recommendations

By

The Work Group who authored the new recommendations was made up of professionals from academic medicine, federal and state public health agencies, and medical societies.

Combating the hepatitis A outbreak in San Diego

Combating the hepatitis A outbreak in San Diego

By

The 3-part plan to halt the outbreak of hepatitis A focuses on immunization, sanitation and education with most of the efforts focused on the homeless population who are the most at-risk population.

Evaluating abnormal liver chemistries: a clinical guideline

Evaluating abnormal liver chemistries: a clinical guideline

By

The American College of Gastroenterology has released recommendations of preferred approaches for diagnosing and evaluating patients with abnormal liver test results.

Excessive energy drink consumption leads to acute hepatitis case

Excessive energy drink consumption leads to acute hepatitis case

By

A 50-year-old man presents to the emergency department with abdominal pain, nausea, jaundice, and dark urine.

Missed blood test results

Missed blood test results

By

A patient's positive hepatitis B results were overlooked for 7 years.

Healthcare issues of the LGBT community: What the primary care clinician should know

Healthcare issues of the LGBT community: What the primary care clinician should know

A greater understanding of the healthcare issues specific to the lesbian, gay, bisexual, and transgender community may improve the quality of care.

Poll indicates many people are unaware of hepatitis B vaccine

Poll indicates many people are unaware of hepatitis B vaccine

More than half of Americans polled were unsure or unaware of the existence of a hepatitis B vaccine.

Intradermal HBV vaccine safe, effective for intramuscular nonresponders

Intradermal HBV vaccine safe, effective for intramuscular nonresponders

No reports of adverse events with intradermal recombinant HBsAg-based vaccine.

Telbivudine prevents mother-to-infant HBV transmission

Telbivudine prevents mother-to-infant HBV transmission

Nearly all pregnant women with hepatitis B virus (HBV) taking telbivudine had undetectable levels of HBV DNA in cord blood.

Hepatitis B treatment 100% effective in preclinical trials

Hepatitis B treatment 100% effective in preclinical trials

The combination of entecavir and birinapant eradicated the hepatitis B virus in preclinical trials.

Increased HBV interventions necessary to reduce transmission

Increased HBV interventions necessary to reduce transmission

Strengthening current hepatitis B virus prevention and treatment efforts can reduce related mortality.

Hepatitis C treatment benefits lupus patients

Hepatitis C treatment benefits lupus patients

Immunosuppressive agents do not increase the risk of HCV flares in anti-HCV-positive lupus patients.

Antiviral treatment improves hepatitis B virus-related hepatocellular carcinoma survival rates

Antiviral treatment improves hepatitis B virus-related hepatocellular carcinoma survival rates

Overall survival was significantly improved for patients treated with nucleoside analogues (NAs) versus those who received no NAs.

Once-daily daclatasvir plus sofosbuvir yields high SVR in HCV

Once-daily daclatasvir plus sofosbuvir yields high SVR in HCV

By

Daclatasvir plus sofosbuvir demonstrated a sustained virological response in 98% of patients with genotype 1 hepatitis C infection.

NIH issues small business grant to encourage hepatitis research

NIH issues small business grant to encourage hepatitis research

Projects funded by the grant will aid public health efforts to reduce the burden of viral hepatitis in the United States.

Community organizations strengthen hepatitis prevention initiatives

Community organizations strengthen hepatitis prevention initiatives

A community-based organization focused on eliminating hepatitis-related health disparities issued a report detailing improvements that can be made for better hepatitis care.

Does extensive hepatitis C screening help or harm?

Does extensive hepatitis C screening help or harm?

By

The risk-benefit profile of more widespread hepatitis C screening is not sufficiently understood, researchers suggest.

Hepatitis C does not cause mental impairment in HIV patients

Hepatitis C does not cause mental impairment in HIV patients

Researchers have eliminated hepatitis C as the cause of impaired mental function in HIV patients.

Sign Up for Free e-newsletters